已收盤 11-20 16:00:00 美东时间
-0.060
-0.15%
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates IRulya Therapeutics (NASDAQ:IRLA) with a Overweight and maintains $70 price target.
11-19 19:39
今日重点评级关注:康托·菲茨杰拉德:维持Lexeo Therapeutics"超配"评级,目标价从23美元升至37美元;摩根士丹利:维持Sana Biotechnology"超配"评级,目标价从12美元升至13美元
11-17 17:31
IRulya Therapeutics (NASDAQ:IRLA) reported quarterly losses of $(2.31) per share which beat the analyst consensus estimate of $(19.83) by 88.35 percent. This is a 95.36 percent increase over losses of $(49.83) per share from the same period last year.
11-13 21:33
IRulya Therapeutics Inc., formerly Quince Therapeutics, Inc., reported its third-quarter 2026 financial results, highlighting a cash position of $105.2 million, expected to fund operations through 2028. The company advanced its LAM-001 program across three indications: Bronchiolitis Obliterans Syndrome (BOS) post lung transplant, Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD), and Sarcoidosis-Associated Pulmonary Hypert...
11-13 13:00
IRulya Therapeutics ( ($IRLA) ) has provided an announcement. On October 19, 20...
10-19 21:23